(2011 - 2012)
2011
2011
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists, and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benefit patients with significant unmet medical needs. The firm in 2020 was spun out of GSK where it was founded in 1985, and has a presence in San Francisco, CA, Philadelphia, PA, and London, UK.
2022
Disrupting extrachromosomal DNA to power the next wave of cancer treatments
2021
2021
Synthetic biology platform for cell therapeutics incubated by the CRISPR Therapeutics founders and SR One. Xap Therapeutics applies CRISPR technology to engineer iPSCs to form functionalised cell products which have the ability to process external cues via engineered receptors and to release various types of cargos upon activation. The ultimate aim is to create novel cell therapies with mechanisms of action that are beyond reach of current approaches, thus bringing a step change improvement in the treatment of serious disease, including autoimmunity and cancer.
2020
Developing highly selective medicines for functionally & genomically defined cancer patients. Novellus' lead asset is a highly differentiate BRAF inhibitor, enabling transformational responses in the additional 50% of patients not currently responsive to existing therapies
2015
2015
UK's leading brand of Cold Pressed Juices and other health drinks and foods. Assisted founder of the business from company inception in 2015 to present. Advised in all matters from strategy to brand positioning to fund raising.
2018
2018
For the last couple of years i have been selecting young emerging artists to support both with my network and financially. The principle is simple, that even the most talented artists struggle at the early stages of their career to make a living from their art. The implication is they spend a substantial amount of their time earning money to pay bills instead of focusing on their craft. I therefore make annual contributions to pay living expenses. These are purely philanthropic, there is no loan to payback. Additionally i help where i can in introducing them to potential buyers, non-traditional exhibition space and anyone else i think could be helpful. My current artist is Victor Seaward: - https://victor-seaward.com/ A London based Painting graduate from the Royal College of Art. Seaward is interested in the agency of things, their material history, and how our visual cultures interact. Mining a broad spectrum of our material cultures to create composite works. Seaward juxtaposes raw, functional materials, such as concrete, with high-tech industrial materials and objects of a historical significance to expose how social and cultural groups create meaning within the material world. The quantum tangle emitted a knot of structure sufficiently complex to reflect, not just the universe outside, but its own inner state.
2017
2017
Pulmocide's two clinical stage, inhaled assets treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life. Unlike currently available treatments for fungal and viral infections in the lung, its innovative approach to drug development provides targeted delivery to the lung so that infections can be treated directly for maximum efficacy and minimal unwanted systemic effects.
2012
2012
Serial investor in UK film producer / director / screenplay writer George Taylor https://www.imdb.com/name/nm1707230/
2015
2015
Clinical small molecule drug discovery company for the treatment of Alzheimer's and other tauopathies. Based in Switzerland. Its lead molecule ASN120290, a modulator of toxic species of Tau, is currently in Phase 1 and plans to move into phase 2 trials in PSP (Progressive supranuclear Palsy), Alzheimer's Disease and other dementias.
2015
2015
Galvanising interest in supporting the festival. Most recently in its pivot towards incorporating dance into its schedule and ultimately combining both opera and ballet into a new and exciting format.